Project cooperationUpdated on 2 February 2026
Insulin and IGF Signalling Mechanisms in Metabolic, Cardiovascular and Cancer Diseases
group leader at IOCB Prague
Praha, Czech Republic
About
We investigate disease-relevant molecular mechanisms of insulin and insulin-like growth factor (IGF1/2) signalling, focusing on receptor specificity, pathway selectivity and dysregulation in metabolic, cardiovascular and cancer-related conditions.
Using synthetic insulin and IGF analogues, peptide mimetics and receptor-selective tools, we dissect metabolic versus mitogenic signalling and their contribution to disease phenotypes. Our work addresses fundamental mechanisms underlying insulin resistance, altered growth signalling and hormone-driven disease progression.
We seek to contribute as a scientific partner to Horizon Europe Health projects focused on disease mechanisms, biomarkers and targeted therapeutic strategies, including topics related to cardiovascular diseases, metabolic disorders and cancer.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
Insulin and IGF Analogues for Targeted Modulation of Metabolic and Mitogenic Signalling
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Jiri Jiracek
group leader at IOCB Prague
Praha, Czech Republic
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Andras Nogradi
Business Development Director at Pharmahungary Group
Budapest, Hungary
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Celia Bengougam
Medical Affairs Team Leader at Withings
Paris, France